Old news about otitis study

Breaking antibiotic resistance in otopathogens
Doctor Stephanie Neville

PROJECT DESCRIPTION

This Project aims to address the critical issue of antibiotic resistance in bacteria that cause middle ear infections (otitis media [OM]). Globally, there are more than 700 million cases of acute OM every year, predominately in children under 5 years old. While most of these infections are cleared by antibiotics before they cause lasting damage, many of the bacteria that infect the middle ear are now resistant to multiple antibiotics, making them very difficult to treat. Rather than attempting to make new antibiotics, this Project proposes to re-energise our existing antibiotics using ionophores. Ionophores are compounds that move metal ions, such as zinc and copper, into bacterial cells where they work in combination with antibiotics to kill the bacteria. Ionophores are safe for human use and our research has shown that they are able to re-sensitise even highly resistant bacteria to current antibiotics. This Project will determine dosing regimens that are able to effectively treat antibiotic resistant OM, and inform improved clinical practice for better patient care.

This project description is from " the 2022 Passe & Wiliams Foundation awardees" report on the 9th of Feb. So she is now determining the needed dosing regimens to re-sensitize the resistant bacteria to current antibiotics used in antibiotic-resistant otitis media.

So at this state, ( and in my opinion only) Dr. Neville could be only working in her lab and testing how much PBT2 is needed for each resistant bacteria with each different antibiotic. Of course, this info is essential before starting to treat otitis patients. This info is also needed before starting patient studies, which will follow, but only after the right "dosing regimens" of PBT2 are known.

This is only my opinion after reading Passe & William's report. IMO, when the clinical studies start, the studies will be registered in Clinical Trials. At the moment, there is nothing and the reason could be that nobody knows the " dosing regimens " of PBT2 with different antibiotics to get each bacteria killed.